Biogen (IDP) Stock Forecast & Price Target

6 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

IDP Analyst Ratings

Moderate Buy

19 Buy

9 Hold

1 Sell

Based on 29 analysts giving stock ratings to

Biogen

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

IDP Stock 12 Month Forecast

Average Price Target

€199.35

▲(11.71% Upside)

Based on 29 Wall Street analysts offering 12 month price targets for Biogen in the last 3 months. The average price target is €199.35 with a high forecast of €263.36 and a low forecast of €137.83. The average price target represents a 11.71% change from the last price of €178.46.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"104":"€104","144":"€144","184":"€184","224":"€224","264":"€264"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":263.363964,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€263.36</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":199.3489631504,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€199.35</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":137.82714116,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€137.83</span>\n  </div></div>","useHTML":true}}],"tickPositions":[104,144,184,224,264],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,185.5,191.4895356923077,197.4790713846154,203.4686070769231,209.45814276923076,215.44767846153846,221.43721415384616,227.42674984615385,233.41628553846155,239.40582123076922,245.39535692307692,251.38489261538462,257.3744283076923,{"y":263.363964,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,185.5,186.56530485772308,187.63060971544616,188.69591457316923,189.7612194308923,190.8265242886154,191.89182914633847,192.95713400406154,194.02243886178462,195.0877437195077,196.15304857723078,197.21835343495385,198.28365829267693,{"y":199.3489631504,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,185.5,181.8328570123077,178.1657140246154,174.49857103692307,170.83142804923077,167.16428506153846,163.49714207384616,159.82999908615383,156.16285609846153,152.49571311076923,148.82857012307693,145.1614271353846,141.4942841476923,{"y":137.82714116,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":105.5,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109.25,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 37, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.95,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.55,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":152.8,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":149.95,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":151.85,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":160.45,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":157.45,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":160.46,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":165.12,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":185.5,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€263.36

Average Price Target€199.35

Lowest Price Target€137.83

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ami Fadia

Needham

€224.74

Buy

25.93%

Upside

Reiterated

07/29/26

12:21 PM 2026 COMPANY UPDATE Biotechnology Biogen Inc. (BIIB) RATING BUY PRICE TARGET $256.00 PREV CLOSE $205.61 52-WEEK RANGE $124.56 - $219.72 2Q26 EPS 2Q26 non-GAAP EPS of $3.60 came in ~20% above cons. of $2.98 driven by higher revenues (+11% or +$279M) and lower R&D (+$17M var) partially offset by higher SG&A (-$52M var).

Myles Minter

William Blair

―

Buy

―

Reiterated

07/29/26

Analysts Offer Insights on Healthcare Companies: Biogen (NASDAQ: BIIB) and Dyne Therapeutics (NASDAQ: DYN)

Laura Chico

Wedbush

€176.45

Hold

-1.12%

Downside

Reiterated

07/29/26

Wedbush Keeps Their Hold Rating on Biogen (BIIB)

Terence Flynn

Morgan Stanley

€194.89

Hold

9.21%

Upside

Reiterated

07/29/26

We expect the stock to trade up slightly this morning, as the focus remains on upcoming pipeline reads.

Emily Field

Barclays

€162.41→€175.58

Hold

-1.62%

Downside

Reiterated

07/29/26

Barclays Sticks to Its Hold Rating for Biogen (BIIB)

David Amsellem

Piper Sandler

€197.52

Buy

10.68%

Upside

Assigned

07/28/26

Piper Sandler Reaffirms Their Buy Rating on Biogen (BIIB)

Jason Zemansky

Bank of America Securities

€188.74

Hold

5.76%

Upside

Reiterated

07/28/26

Analysts Offer Insights on Healthcare Companies: Biogen (NASDAQ: BIIB), Quest Diagnostics (NYSE: DGX) and Otsuka Holdings Co (Other OTC: OTSKF)

Jay Olson

Oppenheimer

€263.36

Buy

47.58%

Upside

Reiterated

07/23/26

Analysts Offer Insights on Healthcare Companies: United Therapeutics (NASDAQ: UTHR), Biogen (NASDAQ: BIIB) and Community Health (NYSE: CYH)

Chris Schott

J.P. Morgan

€162.41

Hold

-8.99%

Downside

Reiterated

07/22/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Amneal Pharmaceuticals (NASDAQ: AMRX), Alnylam Pharma (NASDAQ: ALNY) and Biogen (NASDAQ: BIIB)

Yatin Suneja

Guggenheim

€228.25→€245.81

Buy

37.74%

Upside

Assigned

07/21/26

Biogen price target raised to $280 from $260 at GuggenheimBiogen price target raised to $280 from $260 at Guggenheim

Phil Nadeau

TD Cowen

€188.74

Buy

5.76%

Upside

Reiterated

07/20/26

Analysts Offer Insights on Healthcare Companies: Personalis (NASDAQ: PSNL), UnitedHealth (NYSE: UNH) and Biogen (NASDAQ: BIIB)

Mohit Bansal

Wells Fargo

€219.47

Buy

22.98%

Upside

Reiterated

07/16/26

Analysts Offer Insights on Healthcare Companies: Faeth Therapeutics (NASDAQ: FTH), Oncology Institute (NASDAQ: TOI) and Biogen (NASDAQ: BIIB)

Sumant Kulkarni

Canaccord Genuity

€215.08

Buy

20.52%

Upside

Reiterated

07/15/26

Canaccord Genuity Remains a Buy on Biogen (BIIB)

Evan Seigerman

BMO Capital

€168.51→€172.06

Hold

-3.58%

Downside

Reiterated

07/15/26

BMO Capital Sticks to Its Hold Rating for Biogen (BIIB)

Andrew Fein

H.C. Wainwright

€208.06

Buy

16.58%

Upside

Reiterated

07/14/26

Biogen: CELIA Trial Data Reinforce Tau Leadership, Support Buy Rating and Unchanged $237 Price Target

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ami Fadia

Needham

€224.74

Buy

25.93%

Upside

Reiterated

07/29/26

Myles Minter

William Blair

―

Buy

―

Reiterated

07/29/26

Analysts Offer Insights on Healthcare Companies: Biogen (NASDAQ: BIIB) and Dyne Therapeutics (NASDAQ: DYN)

Laura Chico

Wedbush

€176.45

Hold

-1.12%

Downside

Reiterated

07/29/26

Wedbush Keeps Their Hold Rating on Biogen (BIIB)

Terence Flynn

Morgan Stanley

€194.89

Hold

9.21%

Upside

Reiterated

07/29/26

We expect the stock to trade up slightly this morning, as the focus remains on upcoming pipeline reads.

Emily Field

Barclays

€162.41→€175.58

Hold

-1.62%

Downside

Reiterated

07/29/26

Barclays Sticks to Its Hold Rating for Biogen (BIIB)

David Amsellem

Piper Sandler

€197.52

Buy

10.68%

Upside

Assigned

07/28/26

Piper Sandler Reaffirms Their Buy Rating on Biogen (BIIB)

Jason Zemansky

Bank of America Securities

€188.74

Hold

5.76%

Upside

Reiterated

07/28/26

Analysts Offer Insights on Healthcare Companies: Biogen (NASDAQ: BIIB), Quest Diagnostics (NYSE: DGX) and Otsuka Holdings Co (Other OTC: OTSKF)

Jay Olson

Oppenheimer

€263.36

Buy

47.58%

Upside

Reiterated

07/23/26

Analysts Offer Insights on Healthcare Companies: United Therapeutics (NASDAQ: UTHR), Biogen (NASDAQ: BIIB) and Community Health (NYSE: CYH)

Chris Schott

J.P. Morgan

€162.41

Hold

-8.99%

Downside

Reiterated

07/22/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Amneal Pharmaceuticals (NASDAQ: AMRX), Alnylam Pharma (NASDAQ: ALNY) and Biogen (NASDAQ: BIIB)

Yatin Suneja

Guggenheim

€228.25→€245.81

Buy

37.74%

Upside

Assigned

07/21/26

Biogen price target raised to $280 from $260 at GuggenheimBiogen price target raised to $280 from $260 at Guggenheim

Phil Nadeau

TD Cowen

€188.74

Buy

5.76%

Upside

Reiterated

07/20/26

Analysts Offer Insights on Healthcare Companies: Personalis (NASDAQ: PSNL), UnitedHealth (NYSE: UNH) and Biogen (NASDAQ: BIIB)

Mohit Bansal

Wells Fargo

€219.47

Buy

22.98%

Upside

Reiterated

07/16/26

Analysts Offer Insights on Healthcare Companies: Faeth Therapeutics (NASDAQ: FTH), Oncology Institute (NASDAQ: TOI) and Biogen (NASDAQ: BIIB)

Sumant Kulkarni

Canaccord Genuity

€215.08

Buy

20.52%

Upside

Reiterated

07/15/26

Canaccord Genuity Remains a Buy on Biogen (BIIB)

Evan Seigerman

BMO Capital

€168.51→€172.06

Hold

-3.58%

Downside

Reiterated

07/15/26

BMO Capital Sticks to Its Hold Rating for Biogen (BIIB)

Andrew Fein

H.C. Wainwright

€208.06

Buy

16.58%

Upside

Reiterated

07/14/26

Biogen: CELIA Trial Data Reinforce Tau Leadership, Support Buy Rating and Unchanged $237 Price Target

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

BBOTBridgeBio Oncology Therapeutics

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals Inc

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Biogen

3 Months

Myles MinterWilliam Blair

Success Rate

13/23 ratings generated profit

Average Return

+1.93%

Copying Myles Minter's trades and holding each position for 3 Months would result in 56.52% of your transactions generating a profit, with an average return of +1.93% per trade.

1 Year

Myles MinterWilliam Blair

Success Rate

16/23 ratings generated profit

Average Return

+14.38%

Copying Myles Minter's trades and holding each position for 1 Year would result in 69.57% of your transactions generating a profit, with an average return of +14.38% per trade.

2 Years

Myles MinterWilliam Blair

Success Rate

15/23 ratings generated profit

Average Return

+8.97%

Copying Myles Minter's trades and holding each position for 2 Years would result in 65.22% of your transactions generating a profit, with an average return of +8.97% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IDP Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, IDP has received 46 Buy Ratings, 31 Hold Ratings, and 1 Sell Ratings. IDP average Analyst price target in the past 3 months is 199.35.

Each month's total comprises the sum of three months' worth of ratings.

IDP Financial Forecast

IDP Earnings Forecast

Next quarter’s earnings estimate for IDP is €2.10 with a range of €1.50 to €3.47. The previous quarter’s EPS was €3.16. IDP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year IDP has Performed in-line its overall industry.

IDP Sales Forecast

Next quarter’s sales forecast for IDP is €2.25B with a range of €2.11B to €2.39B. The previous quarter’s sales results were €2.40B. IDP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 66.67% of the time in the same period. In the last calendar year IDP has Performed in-line its overall industry.

IDP Stock Forecast FAQ

What is DE:IDP’s average 12-month price target, according to analysts?

Based on analyst ratings, Biogen’s 12-month average price target is 199.35.

What is DE:IDP’s upside potential, based on the analysts’ average price target?

Biogen has 11.71% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Biogen a Buy, Sell or Hold?

Biogen has a consensus rating of Moderate Buy, which is based on 19 buy ratings, 9 hold ratings and 1 sell ratings.

What is Biogen’s share price target?

The average share price target for Biogen is 199.35. This is based on 29 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €263.36 ,and the lowest forecast is €137.83. The average share price target represents 11.71% Increase from the current price of €178.46.

What do analysts say about Biogen?

Biogen’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 29 Wall Streets Analysts.

How can I buy shares of Biogen?

To buy shares of DE:IDP, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Biogen (IDP) Stock Forecast & Price Target

IDP Analyst Ratings

IDP Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Biogen

IDP Analyst Recommendation Trends

IDP Financial Forecast

IDP Earnings Forecast

IDP Sales Forecast

IDP Stock Forecast FAQ

Detailed List of Analyst Forecasts